These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 34984721)

  • 1. Radioiodination of balsalazide, bioevaluation, and characterization as a highly selective radiotracer for imaging of ulcerative colitis in mice.
    Sanad MH; Gomaa NM; El Bakary NM; Ibrahim IT; Massoud A
    J Labelled Comp Radiopharm; 2022 Mar; 65(3):71-82. PubMed ID: 34984721
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Radiosynthesis and in silico bioevaluation of
    Sanad MH; Rizvi SFA; Farag AB
    Chem Biol Drug Des; 2021 Nov; 98(5):751-761. PubMed ID: 34314572
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A randomized, double blind, dose-response comparison of balsalazide (6.75 g), balsalazide (2.25 g), and mesalamine (2.4 g) in the treatment of active, mild-to-moderate ulcerative colitis.
    Levine DS; Riff DS; Pruitt R; Wruble L; Koval G; Sales D; Bell JK; Johnson LK
    Am J Gastroenterol; 2002 Jun; 97(6):1398-407. PubMed ID: 12094857
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Balsalazide is superior to mesalamine in the time to improvement of signs and symptoms of acute mild-to-moderate ulcerative colitis.
    Pruitt R; Hanson J; Safdi M; Wruble L; Hardi R; Johanson J; Koval G; Riff D; Winston B; Cross A; Doty P; Johnson LK
    Am J Gastroenterol; 2002 Dec; 97(12):3078-86. PubMed ID: 12492193
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Balsalazide: a review of its therapeutic use in mild-to-moderate ulcerative colitis.
    Muijsers RB; Goa KL
    Drugs; 2002; 62(11):1689-705. PubMed ID: 12109930
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Low dose balsalazide (1.5 g twice daily) and mesalazine (0.5 g three times daily) maintained remission of ulcerative colitis but high dose balsalazide (3.0 g twice daily) was superior in preventing relapses.
    Kruis W; Schreiber S; Theuer D; Brandes JW; Schütz E; Howaldt S; Krakamp B; Hämling J; Mönnikes H; Koop I; Stolte M; Pallant D; Ewald U
    Gut; 2001 Dec; 49(6):783-9. PubMed ID: 11709512
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Balsalazide is more effective and better tolerated than mesalamine in the treatment of acute ulcerative colitis. The Abacus Investigator Group.
    Green JR; Lobo AJ; Holdsworth CD; Leicester RJ; Gibson JA; Kerr GD; Hodgson HJ; Parkins KJ; Taylor MD
    Gastroenterology; 1998 Jan; 114(1):15-22. PubMed ID: 9428213
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A double-blind comparison of balsalazide, 6.75 g, and sulfasalazine, 3 g, as sole therapy in the management of ulcerative colitis.
    Mansfield JC; Giaffer MH; Cann PA; McKenna D; Thornton PC; Holdsworth CD
    Aliment Pharmacol Ther; 2002 Jan; 16(1):69-77. PubMed ID: 11856080
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Balsalazide disodium for the treatment of ulcerative colitis.
    Patil SA; Moss AC
    Expert Rev Gastroenterol Hepatol; 2008 Apr; 2(2):177-84. PubMed ID: 19072352
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A double-blind comparison of balsalazide, 6.75 g daily, and sulfasalazine, 3 g daily, in patients with newly diagnosed or relapsed active ulcerative colitis.
    Green JR; Mansfield JC; Gibson JA; Kerr GD; Thornton PC
    Aliment Pharmacol Ther; 2002 Jan; 16(1):61-8. PubMed ID: 11856079
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Low-dose balsalazide plus a high-potency probiotic preparation is more effective than balsalazide alone or mesalazine in the treatment of acute mild-to-moderate ulcerative colitis.
    Tursi A; Brandimarte G; Giorgetti GM; Forti G; Modeo ME; Gigliobianco A
    Med Sci Monit; 2004 Nov; 10(11):PI126-31. PubMed ID: 15507864
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Balsalazide.
    Prakash A; Spencer CM
    Drugs; 1998 Jul; 56(1):83-9; discussion 90. PubMed ID: 9664201
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Balsalazide plus high-potency probiotic preparation (VSL[sharp]3) in the treatment of acute mild-to-moderate ulcerative colitis and uncomplicated diverticulitis of the colon.
    Tursi A
    J Clin Gastroenterol; 2008 Sep; 42 Suppl 3 Pt 1():S119-22. PubMed ID: 18806701
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Patient-led variable dosing with balsalazide as long-term therapy for maintenance in ulcerative colitis: a 3-year prospective observational study.
    Green JR; Swan CH; Gibson JA; Kerr GD; Swarbrick ET; Thornton PC
    Aliment Pharmacol Ther; 2004 Feb; 19(4):435-42. PubMed ID: 14871283
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Radioiodination and biological evaluation of nizatidine as a new highly selective radiotracer for peptic ulcer disorder detection.
    Sanad MH; Saleh GM; Marzook FA
    J Labelled Comp Radiopharm; 2017 Nov; 60(13):600-607. PubMed ID: 28833386
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Maintenance of remission of ulcerative colitis: a comparison between balsalazide 3 g daily and mesalazine 1.2 g daily over 12 months. ABACUS Investigator group.
    Green JR; Gibson JA; Kerr GD; Swarbrick ET; Lobo AJ; Holdsworth CD; Crowe JP; Schofield KJ; Taylor MD
    Aliment Pharmacol Ther; 1998 Dec; 12(12):1207-16. PubMed ID: 9882028
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combined Parthenolide and Balsalazide Have Enhanced Antitumor Efficacy Through Blockade of NF-κB Activation.
    Kim SL; Kim SH; Park YR; Liu YC; Kim EM; Jeong HJ; Kim YN; Seo SY; Kim IH; Lee SO; Lee ST; Kim SW
    Mol Cancer Res; 2017 Feb; 15(2):141-151. PubMed ID: 28108625
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Balsalazide: a novel 5-aminosalicylate prodrug for the treatment of active ulcerative colitis.
    Wiggins JB; Rajapakse R
    Expert Opin Drug Metab Toxicol; 2009 Oct; 5(10):1279-84. PubMed ID: 19743890
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of mesalazine and balsalazide in induction and maintenance of remission in patients with ulcerative colitis: a meta-analysis.
    Rahimi R; Nikfar S; Rezaie A; Abdollahi M
    Dig Dis Sci; 2009 Apr; 54(4):712-21. PubMed ID: 18683049
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Short report: comparison of two doses of balsalazide in maintaining ulcerative colitis in remission over 12 months.
    Green JR; Swan CH; Rowlinson A; Gibson JA; Brown P; Kerr GD; Swarbrick ET; Thornton P
    Aliment Pharmacol Ther; 1992 Oct; 6(5):647-52. PubMed ID: 1420754
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.